Ethic Inc. Has $1.48 Million Holdings in Fresenius Medical Care AG & Co. KGaA $FMS

Ethic Inc. grew its stake in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 2.8% in the 2nd quarter, HoldingsChannel reports. The fund owned 52,497 shares of the company’s stock after purchasing an additional 1,413 shares during the quarter. Ethic Inc.’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $1,481,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Wayfinding Financial LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA during the first quarter worth approximately $25,000. Spire Wealth Management acquired a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the first quarter valued at approximately $27,000. Brooklyn Investment Group raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 424.5% in the first quarter. Brooklyn Investment Group now owns 1,285 shares of the company’s stock valued at $32,000 after buying an additional 1,040 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 33.3% in the first quarter. Russell Investments Group Ltd. now owns 4,200 shares of the company’s stock valued at $105,000 after buying an additional 1,049 shares in the last quarter. Finally, TD Private Client Wealth LLC raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 6,380.3% in the second quarter. TD Private Client Wealth LLC now owns 4,925 shares of the company’s stock valued at $141,000 after buying an additional 4,849 shares in the last quarter. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. UBS Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research report on Wednesday, October 15th. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 12th. Zacks Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Wall Street Zen upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, Bank of America cut shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research note on Wednesday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $27.80.

Fresenius Medical Care AG & Co. KGaA Price Performance

Shares of NYSE:FMS opened at $27.29 on Friday. The company’s 50 day simple moving average is $25.88 and its 200 day simple moving average is $26.44. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.44 and a quick ratio of 1.08. Fresenius Medical Care AG & Co. KGaA has a 1 year low of $18.94 and a 1 year high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.02. The business had revenue of $5.54 billion for the quarter, compared to analysts’ expectations of $5 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. Analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.